ARTICLE | Clinical News
DMT210: Ph II DMT210-02 started
December 9, 2016 12:05 AM UTC
Dermata began the double-blind, vehicle-controlled, U.S. Phase II DMT210-002 trial to evaluate twice-daily topical DMT210 gel for 28 days in 25 patients. Dermata has exclusive, worldwide rights to DMT...